An emerging and promising anticancer strategy: colonization of engineered Staphylococcus epidermidis

作者
Yanyan Liu,Yulong Cai
出处
期刊:MedComm [Wiley]
卷期号:5 (1): e467-e467
标识
DOI:10.1002/mco2.467
摘要

A recent study published in the journal Science by Chen et al.1 proposed an emerging and promising anticancer strategy that utilizes engineered skin bacteria to treat or prevent melanoma. The research shed light on the potential of microbiome to modulate host immunity and offered novel insights into the application of commensal microorganisms in human diseases. After a long period of coevolution, humans live in symbiosis with a variety of microorganisms, including gut microbes, skin symbionts, fungi, and viruses. Among them, skin microorganisms are a complex group containing bacteria, fungi, and viruses, which are involved in constituting the first protective barrier for humans.2 It is worth mentioning that symbiotic bacteria have two roles that should not be overlooked: they are involved in the regulation of the local or systemic immune environment, and bacterial proteins can induce specific immune responses.3 For instance, in 2012, a study reported that the skin microbiota can actively control local inflammatory responses and regulate resident T lymphocyte function.4 Moreover, utilizing the immune function of the body is one of the significant tumor therapies. Based on these understandings, we would raise the question, could these interactions be used for antitumor therapy? Prof. Michael A. Fischbach's group from Stanford University explored this question and gave us the answer (Figure 1).1 Staphylococcus epidermidis is a ubiquitous bacterium that colonizes the human skin and plays a significant role in the barrier development, maintenance of homeostasis and controlling of opportunistic pathogens.5 First, the researchers expressed the tumor antigens in S. epidermidis and found that skin commensal-induced T cells were able to recognize tumors specifically. This allowed for the observation of whether these T cells were able to infiltrate the tumor and participate in a cytotoxic attack on the tumor. To be specific, they constructed 13 mutant strains of S. epidermidis using a specialized DNA-importing system with an Escherichia coli DC10B passaging plasmid, heat shock, and hyperosmolar sorbitol. Next, S. epidermidis NIHLM087 was selected to express unnatural antigens and ovalbumin (OVA) was used as a model antigen. Three groups of strains with different antigen properties and localization were constructed. S. epidermidis expressing two antigenic peptides from OVA, OT-I and OT-II, could stimulate OVA-specific CD8+ or CD4+ T cells, respectively. There are three different antigenic localizations, including cytoplasmic (represented by “c”), covalently bound to the cell wall (represented by “w”), and secreted extracellularly (represented by “s”). Through colonization with S. epidermidis expressing either unrelated or related antigens before subcutaneous injection of B16-F0-OVA (an OVA-expressing melanoma cell line) into mice, it was discovered that S. epidermidis has antitumor activity only in the presence of OVA, indicating that OVA-specific T cells are required for the antitumor effect. Additionally, the absence of antitumor responses in heat-inactivated S. epi-OVApep (a combination of S. epi-wOT-I and S. epi-sOT-II) suggested that the engineered bacteria not only act as antigens and adjuvants, but their ability to survive, occupy specialized ecological niches, and prolonged antigen exposure are probably necessary for immune stimulation responses. The antitumor activity was lost when mice were not related to both S. epi-wOT-I and S. epi-sOT-II combinations, suggesting that the necessary conditions for the antitumor effect are OVA-specific CD8+ T and CD4+ T cells. Besides in situ and near colonization, they examined whether the engineered S. epidermidis-induced T cells could migrate to other tissues. If so, whether the displacement of microbial colonists that can lead to sepsis is a potential concern. By using B16-F10, a highly aggressive model of metastatic melanoma, the study showed that the antitumor effect of S. epi-OVA is not limited to the skin and subcutaneous tissues. Colonization with S. epi-OVA significantly impeded the growth of lung metastatic melanoma cells. S. epi-OVA-induced T cells limited aggressive tumor growth even as monotherapy, and meanwhile, the treatment is mild and does not cause any immune side effects, which obviates the previous concern. Encouraged by these positive results, the researchers proceeded to explore whether the engineered S. epidermidis expressing other tumor antigens could induce specific T cell responses, further exerting antitumor effects. They then engineered S. epidermidis to express two neoantigenic peptides from B16-F10 melanoma (termed S. epi-neoAg). Prophylactic colonization of S. epi-neoAg effectively suppressed subsequent metastatic tumor growth. Besides, they evaluated the therapeutic effect of engineered S. epidermidis by colonizing S. epi-OVApep at 3 days after intravenous inoculation of B16-F10-OVA (a melanoma cell line expressing OVA) in the metastatic melanoma model. The inhibition of tumor growth in the treatment model was comparable to that in the prevention model, and OVA-specific CD8+ T cells in the lung and spleen increased. The result supports the importance of S. epi-OVApep-induced CD8+ T cells in controlling melanoma metastasis. In addition, although S. epi-OVA-induced and tumor-induced T cells have the same antigen specificity, they exhibit different functions. The composition of OVA-specific CD8+ T cell population was altered, with the majority of central memory T cells in the control group and effector T cells and effector memory T cells in the S. epi-OVApep group. Nevertheless, the effector T and effector memory T cells could be exhausted in the tumor environment, and the tumor-infiltrating lymphocytes induced by S. epi-OVA highly expressed the marker of exhaustion, programmed cell death protein-1. Consequently, they further found that the combination of engineered S. epidermidis with immune checkpoint inhibitors could produce a durable and effective antitumor response to treat established melanoma without significant adverse effects, implying the broad application prospect of antitumor therapy exerted by engineered S. epidermidis. This study has demonstrated the antigen-specific antitumor potential of engineered S. epidermidis, offering promising prospects for future cancer therapeutics. Moreover, it opens up possibilities for incorporating antigen expression into other commensal microorganisms to induce a broad immune response against various antigens. This compelling study suggests an early but encouraging anticancer strategy. However, it is crucial to acknowledge that S. epidermidis is commonly encountered as an opportunistic pathogen.5 Since S. epidermidis also inhabits the gut, antigen-expressing S. epidermidis strains in the skin may lead to contamination of other nonskin microorganisms in vivo, triggering systemic antimicrobial immune responses. Also, engineered commensals may also induce tolerance responses, particularly in certain autoimmune diseases, allergic diseases, and chronic inflammatory conditions. Meanwhile, there has been more research on the relationship between gut microbes and immune function, and a lack of research on skin symbiotic bacteria, which also play an essential role in immune function. Therefore, a large number of in-depth studies are warranted. In addition, research in multiple classical cancer models would be beneficial in expanding the application of engineered bacteria. Since the structure and function of the mouse and human body are quite different, additional animal model studies are imperative. Moreover, thorough research on the interaction between the commensal microbiota and the host is beneficial to enhance the safety and efficacy of this therapy for a better clinical application. Y. C. conceptualized the research highlight and Y. L. wrote the manuscript and drew the figure. Both the authors have read and approved the final manuscript. We really appreciate the specialized mapping software Biorender. The authors declare no conflict of interests. This work has no relevant funding. No ethics approval was required for this review that did not involve patients or patient data. Not applicable.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
白圭发布了新的文献求助10
刚刚
刚刚
刚刚
S0urC3完成签到,获得积分10
刚刚
u0u0uu0发布了新的文献求助10
1秒前
1秒前
gfhdf完成签到,获得积分10
1秒前
1秒前
纯真的飞绿完成签到,获得积分10
2秒前
2秒前
非凡完成签到,获得积分10
2秒前
李鲤鱼发布了新的文献求助10
2秒前
3秒前
Bella发布了新的文献求助10
3秒前
Ava的应助被自然的凌兰采纳,获得10
4秒前
小叶子发布了新的文献求助10
4秒前
zuoyou发布了新的文献求助10
4秒前
CJY发布了新的文献求助10
4秒前
4秒前
wyx发布了新的文献求助20
4秒前
君怀柔完成签到,获得积分10
4秒前
今后的应助被醋溜滑板采纳,获得10
5秒前
满鑫完成签到,获得积分10
5秒前
6秒前
6秒前
沐沐完成签到,获得积分20
6秒前
7秒前
脑洞疼的应助被沟通亿心采纳,获得10
8秒前
李健的粉丝团团长的应助被Mei采纳,获得10
8秒前
8秒前
8秒前
眼睛大行云完成签到,获得积分10
9秒前
9秒前
10秒前
含糊的白曼完成签到 ,获得积分10
10秒前
AccompanyX发布了新的文献求助10
10秒前
万能图书馆的应助被Echor采纳,获得30
10秒前
无极微光的应助被蓓蓓采纳,获得20
10秒前
11秒前
慕青的应助被ww采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519